Illumina raises FY26 guidance on Q2 strength and NovaSeq X momentum
Jul 30, 2026, 4:12 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The earnings beat and higher full-year guidance imply higher intrinsic value and potential multiple expansion for ILMN. Positive drivers include sustained NovaSeq X momentum and ROW growth; risks include regulatory/currency dynamics in China and integration costs from acquisitions. Historically, similar upgrades in sequencing peers have led to short-term upside followed by volatility on macro data.
AI summary
What happened, with direct paths to the underlying reporting
Illumina posted a strong Q2 2026 with revenue of $1.159B, up 9.5% YoY, and margins above 21%. The company lifted full-year guidance to $4.60–$4.64B and non-GAAP EPS to $5.30–$5.40, driven by NovaSeq X demand and higher ROW growth. The raise suggests a higher growth trajectory if demand sustains.
Q2 2026 revenue $1.159B; +9.5% YoY.
FY2026 revenue guidance raised to $4.60-$4.64B.
ROW organic growth guidance >5%; NovaSeq X demand robust.
GAAP margin 21.1%; Non-GAAP 22.5%.
End cash $1.17B; OCF $201M; FCF $162M.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Illumina (ILMN) benefits from CMS reimbursement of $2,989.55 for its TruSight Oncology test, expected to boost genomic profiling adoption. This positive momentum aligns with analy…
